Geneuro Logo

Geneuro

GEM | PA

Overview

Corporate Details

ISIN(s):
CH0308403085
LEI:
213800FUJCKXO9LK3444
Country:
Switzerland
Address:
chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

GeNeuro is a Swiss-based, clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and autoimmune diseases. The company utilizes a novel therapeutic approach that targets pathogenic proteins encoded by human endogenous retroviruses (HERVs), which are believed to contribute to the progression of diseases such as Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and post-COVID conditions. Its main drug candidate, temelimab, is being developed to treat the cognitive and fatigue symptoms associated with Long COVID. In July 2024, the company was granted a debt-restructuring moratorium.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Geneuro. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-30 19:37
Post-Annual General Meeting Information
Inside Information / Other news releases
English 224.5 KB
2025-06-30 19:37
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 753.1 KB
2025-06-12 22:42
Legal Proceedings Report
Inside Information / Other news releases
English 204.9 KB
2025-06-12 22:42
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 203.8 KB
2025-06-10 18:24
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 207.4 KB
2025-06-10 18:24
Pre-Annual General Meeting Information
Inside Information / Other news releases
English 209.5 KB
2025-05-27 18:00
Legal Proceedings Report
Inside Information / Other news releases
English 162.5 KB
2025-05-27 18:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 187.1 KB
2025-05-12 18:36
Report Publication Announcement
Inside Information / Other news releases
English 481.8 KB
2025-05-12 18:36
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 669.5 KB

Automate Your Workflow. Get a real-time feed of all Geneuro filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Geneuro via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Elicera Therapeutics AB Logo
Clinical-stage developer of CAR T-cell and oncolytic virus therapies for cancer treatment.
Sweden ELIC
Enlivex Therapeutics Ltd. Logo
Developing a cell therapy platform to treat inflammatory diseases by reprogramming macrophages.
Israel ENLV
E-Novia Logo
A deep-tech factory building Physical AI ventures for mobility, logistics, and automation.
Italy E9IA
ERYTECH Pharma S.A. Logo
Biopharma firm developing phage therapies to fight antimicrobial resistance (AMR).
France ERYP
EUROESPES Logo
Research & patient care for CNS diseases via personalized genomic medicine.
Spain EEP
Eurofins-Cerep Logo
CRO offering preclinical drug profiling, screening & pharmacology testing for pharma/biotech.
France ALECR
Evogene Ltd. Logo
An AI-powered computational biology platform for life-science products in health and agriculture.
Israel EVGN
Evotec SE Logo
A drug discovery and development partner for pharma, biotech, and academia.
Germany EVT
EXACT Therapeutics AS Logo
Biopharma developing ultrasound technology for targeted drug delivery in oncology.
Norway EXTX
ExpreS2ion Biotech Holding AB Logo
Develops vaccines and immunotherapies for infectious diseases and cancer using a protein platform.
Sweden EXPRS2